Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352557 | 0.82 | KDM4E (0.60) | HTTPTK2BKDM4EHPGDMEN1 | |
| SCHEMBL28370434 | 0.82 | KDM4E (0.60) | HTTPTK2BKDM4EHPGDMEN1 | |
| SCHEMBL6236426 | 0.78 | HTT (1.00) | HTTPTK2BKDM4EHPGDMEN1 | |
| SCHEMBL797563 | 0.76 | KDM4E (1.00) | HTTKDM4EHPGDMEN1CYP1A2 | |
| SCHEMBL6350624 | 0.73 | KDM4E (0.69) | HTTKDM4EHPGDMEN1CYP1A2 | |
| SCHEMBL18319338 | 0.72 | KDM4E (0.49) | HTTPTK2BKDM4EHPGDMEN1 | |
| SCHEMBL7500905 | 0.72 | PLK4 (0.62) | HTTKDM4EHPGDMEN1CYP1A2 | |
| SCHEMBL16923048 | 0.71 | KDM4E (0.62) | HTTPTK2BKDM4EHPGDMEN1 | |
| SCHEMBL797996 | 0.70 | PARP1 (0.64) | HTTPTK2BPARP1MAPT | |
| SCHEMBL30233773 | 0.70 | PARP1 (0.64) | HTTPTK2BPARP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-110790762-A | Tetrahydroindole quinazoline compound and application thereof | 中国医学科学院医药生物技术研究所 | 2020-02-14 | — | — | CN | disclosed |
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | HTT 3086/4885PTK2B 77/4885KDM4E 1947/4885 |
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | HTT 3748/4885PTK2B 58/4885KDM4E 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.